Obamacare sign-ups on track to hit 7 million, sources say
The 7 million target, thought to be out of reach by most experts, was in sight on a day that saw surging consumer interest as well as vexing computer glitches.
The 7 million target, thought to be out of reach by most experts, was in sight on a day that saw surging consumer interest as well as vexing computer glitches.
The last-minute flood of applicants in Indiana mirrored national trends as people sought to at least start the process Monday.
For now, at least, the year-to-year price increases of individual insurance under Obamacare look a lot like they did before Obamacare. That’s not a failure, but it’s not a success either.
Indiana University Health’s business deteriorated last year in nearly every area. But price hikes and a surge in outpatient visits to Indianapolis-area facilities mostly offset those problems.
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Afrezza, a powdered insulin used through an inhaler, would be the MannKind Corp.’s first marketed product. The treatment would compete against Lilly’s Humalog. An FDA report tied the drug to a decline in lung function.
Like much else about Obama's health care law, the milestone comes with a caveat: The administration has yet to announce how many consumers actually closed the deal by paying their first month's premium.
When patients at Indianapolis-area hospitals pay their bills, they're not just funding their own health care. They're contributing to the care of Hoosiers in the rest of the state, too, especially care provided by hospital-employed physicians.
People who've started applying for health insurance but aren't able to finish before the March 31 enrollment deadline will get extra time, the Obama administration announced Tuesday.
Minors under 16 no longer can hop into a tanning bed at Indiana salons, even with parental supervision.
Two months before health insurers must submit rate proposals for 2015 to government regulators, WellPoint Inc. fired a surprising shot across their bow.
Franciscan Alliance, always the first to report its year-end financial results, put out numbers that show a real decline in profit from operations of 58 percent.
The health insurer predicted growth in government-funded health insurance programs would push revenue above $100 billion by 2018. That prompted investors to push WellPoint stock above $100 per share—an all-time high for the company.
Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Dow AgroSciences is getting a new chief, the company said Friday. Meanwhile, the CEO of parent company Dow Chemical says Dow Agro could be sold off in a year or two.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
WellPoint is already raising a 2014 earnings forecast it laid out earlier this year, but the nation’s second-largest health insurer’s projections are still below analyst expectations.
Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.